Xencor, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XNCR research report →
Range $27 – $27
Price Chart
About the company
Xencor Inc. , a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders.
- CEO
- Bassil I. Dahiyat
- IPO
- 2013
- Employees
- 260
- HQ
- Pasadena, CA, US
Get TickerSpark's AI analysis on XNCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.46B
- P/E
- -8.58
- PEG
- 0.12
- P/S
- 14.96
- P/B
- 2.87
- EV/EBITDA
- -12.28
- Div Yield
- 0.00%
- Gross Margin
- 36.15%
- Op Margin
- -217.93%
- Net Margin
- -177.10%
- ROE
- -28.77%
- ROIC
- -30.58%
Latest fiscal year · YoY change
- Revenue
- $125.58M+13.7%
- Gross Profit
- $115.06M+198.2%
- Op Income
- $-177,502,000
- Net Income
- $-91,923,000+60.5%
- EPS
- $-1.24+65.4%
- OCF Growth
- +33.2%
- FCF Growth
- +33.6%
- 52W High
- $21.26
- 52W Low
- $6.92
- 50D MA
- $13.47
- 200D MA
- $13.51
- Beta
- 0.86
- RSI (14)
- 74
- Avg Volume
- 893.47K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the XNCR Q4 '23 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 73.4%
- Shares Outstanding
- 74.14M
- Float Shares
- 54.42M
of shares held by institutions
202 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 13.04M | ▲ 1.11M |
| Primecap Management Co | 10.34M | ▲ 119.70K |
| Vanguard Group Inc | 7.17M | ▲ 61.69K |
| Bvf Inc/Il | 7.13M | 0 |
| Rtw Investments, LP | 6.78M | 0 |
| Ra Capital Management, L.P. | 4.90M | ▲ 4.90M |
| State Street Corp | 4.35M | ▼ 155.22K |
| Tcg Crossover Management, LLC | 2.45M | 0 |
| Ecor1 Capital, LLC | 2.18M | ▼ 1.07M |
| Geode Capital Management, LLC | 1.82M | ▲ 62.66K |
| Price T Rowe Associates Inc | 1.56M | ▼ 41.34K |
| Morgan Stanley | 1.56M | ▲ 49.56K |
Held by 240 ETFs
Biggest fund positions in XNCR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Feigal Ellen | other | 10,302 |
| Jun 16, 26 | Feigal Ellen | other | 20,604 |
| Jun 16, 26 | GORMAN KEVIN CHARLES | other | 10,302 |
| Jun 16, 26 | GORMAN KEVIN CHARLES | other | 20,604 |
| Jun 16, 26 | GUSTAFSON KURT A | other | 10,302 |
| Jun 16, 26 | GUSTAFSON KURT A | other | 20,604 |
| Jun 16, 26 | Klencke Barbara | other | 10,302 |
| Jun 16, 26 | Klencke Barbara | other | 20,604 |
| Jun 16, 26 | Montgomery Alan Bruce | other | 10,302 |
| Jun 16, 26 | Montgomery Alan Bruce | other | 20,604 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XNCR coverage
Recent articles, reports, and earnings notes.
Vesicor Therapeutics Is Going Public via SPAC — Here’s the Setup
Vesicor Therapeutics, a preclinical oncology gene-therapy company, is going public via merger with Black Hawk Acquisition Corp (BKHA). The deal is still pending in the latest June 2026 filing, and the setup hinges on whether redemptions and dilution leave enough capital for a real biotech runway.
Veraxa Biotech AG IPO: What Investors Need to Know
Veraxa Biotech AG Ordinary Shares (NASDAQ: VRXA) is expected to list on 2026-06-10, but the price range has not been disclosed. This is a SPAC business combination rather than a traditional IPO, with the story centered on a pre-commercial oncology pipeline. Bull case: a differentiated antibody-therapy platform; bear case: no product revenue yet and heavy financing needs.
Want a deeper read on XNCR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
zacks.com · Jul 20
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
businesswire.com · Jul 17
Xencor: Bullish On Their Increasingly In-House Pipeline
seekingalpha.com · Jul 14
The Biology Came First.
gurufocus.com · May 18
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com · May 13
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
zacks.com · May 6
Xencor Reports First Quarter 2026 Financial Results
businesswire.com · May 6
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
seekingalpha.com · May 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Bullish or bearish?
Where do you stand on XNCR?